ArticleCureus2026
Dapsone-Induced Systemic Drug Reaction in a Patient With Immunoglobulin A Vasculitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dapsone is widely used for inflammatory dermatoses and vasculitides but may cause severe systemic hypersensitivity reactions. Diagnosis can be challenging when clinical features overlap with underlying inflammatory disease and when eosinophilia is absent. We report a case of a young man with biopsy-confirmed immunoglobulin A vasculitis (Henoch-Schönlein purpura) who developed facial and neck edema, a diffuse morbilliform eruption, and hepatocellular liver injury approximately four weeks after initiation and dose escalation of dapsone. Laboratory evaluation demonstrated elevated aminotransferases with normal creatinine and absent eosinophilia, along with anemia and reticulocytosis suggestive of concurrent dapsone-related hematologic toxicity. The patient was receiving ongoing cyclosporine and had recent high-dose corticosteroid exposure at the time of presentation. Dapsone was discontinued and systemic corticosteroids were administered with rapid clinical improvement. This case highlights diagnostic pitfalls in recognizing severe drug reactions in immunosuppressed patients and emphasizes the importance of integrating medication timelines, organ involvement, and immunosuppression status when evaluating suspected drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.